Cost-Effectiveness of Universal Repeat Human Immunodeficiency Virus Screening in Pregnancy: A Cross-Sectional Study from Western India.
Indian J Community Med
; 46(4): 668-672, 2021.
Article
em En
| MEDLINE
| ID: mdl-35068731
ABSTRACT
OBJECTIVE:
The objective of the study was to evaluate the cost-effectiveness of universal repeat human immunodeficiency virus (HIV) screening late in pregnancy as opposed to the existing system of single HIV test early in pregnancy.BACKGROUND:
Strategy of universal repeat HIV screening in pregnancy to achieve Elimination of mother to child transmission in a low prevalence setting such as India should be examined from the cost-effectiveness point of view.METHODOLOGY:
In a cross-sectional study, 2500 pregnant women with 32 weeks gestation or more and screened HIV nonreactive at least 3 months before the study were offered repeat HIV screening. A decision analysis model was used to determine cost-effectiveness of a repeat HIV screening late in pregnancy in both government (societal) and healthcare payer perspectives, followed by one-way sensitivity analysis at different rates of incident HIV in pregnancy.RESULTS:
The incidence of HIV infection during pregnancy was 1.18/1000 women years (95% confidence interval 0.29-4.7). The existing system of single HIV test is 1.9 times costlier per quality adjusted life years gained than the proposed system of repeat HIV screening.CONCLUSION:
When the incidence of HIV in pregnancy is 1.18/1000 woman-years, even in settings with antenatal HIV positivity rates as low as 0.01%, repeat HIV screening in pregnancy is cost effective.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Índia